Meet Our Team

Tom Shea is the founding President of Xentria overseeing all aspects of business development, clinical, regulatory, and commercial operations. Tom is also the founding CEO of Meitheal Pharmaceutical, Inc., a generic pharmaceutical company focused on development, manufacture and supply of generic injectable products, which was established in January 2017.

Prior to joining Xentria and Meitheal, Tom was Vice President of Global Alliance Management for Sagent Pharmaceuticals and was responsible for global partnerships, supply chain and product development. Before his work at Sagent, Tom held various roles at APP, now Fresenius Kabi North America, in Commercial Operations and Business Development, focusing on Portfolio Management and National Accounts.

Tom started his pharmaceutical career as a Sales Rep at Fougera, now Sandoz. During his tenure at Fougera, he held positions of increasing responsibilities eventually attaining the position of National Sales Manager. Tom earned an M.B.A. from Notre Dame University and a B.A. in Philosophy from Marquette University.

Kirsten Anderson is Xentria’s Chief Operating Officer. Kirsten leads all strategic, operational, and clinical activities for Xentria. She is responsible for driving organizational vision, operational strategy, and translating strategy into actionable steps for growth. Kirsten is a clinical research leader specializing in growth strategy, with expertise in oncology drug development.  She has 30 years of experience in the biotech industry, most recently as Senior Vice President of Clinical Development at Presage Biosciences, responsible for strategic oversight of clinical research, including trial design, regulatory, operations, pharmacovigilance and biometrics. She has held leadership positions at OncoGenex, Sonus Pharmaceuticals, Xcyte Therapies, and Immunex. Kirsten earned a Master’s in Biotech Enterprise from Johns Hopkins University and has a bachelor’s degree in biology from the University of Vermont.

Victoria is the General Counsel & Corporate Secretary of Xentria overseeing all legal and corporate governance matters. Victoria is also the General Counsel & Corporate Secretary of Meitheal Pharmaceutical, Inc., a generic pharmaceutical company focused on development, manufacture and supply of generic injectable products, which was established in January 2017.

Prior to joining Xentria and Meitheal, Victoria worked for Sagent Pharmaceuticals where she most recently served as Associate General Counsel and Assistant Secretary. Victoria started her legal career in private law practice in Chicago, Illinois. She has experience in acquisitions and dispositions, corporate and security transactions and intellectual property matters, including both domestic and international business transactions, litigation management and regulatory and quality assurance compliance.

Victoria earned her J.D. and LL.M in Intellectual Property from the John Marshall Law School and her B.S. in Operations Management & Information Systems from Northern Illinois University.

Jennifer has supported Xentria in the capacity of Executive Vice President of Operations since its inception and is a key part of the leadership team. During this time, she has spearheaded operations, project management, production and supply chain functions. Prior to supporting Xentria, Jennifer held various positions at Sagent Pharmaceuticals in global alliance management (focusing on commercial supply management), new product launches, and project management.  Her last position with Sagent was Sr. Director of Project Management  where she was responsible for product development and commercial manufacturing partnerships.

Jennifer started her pharmaceutical career at Hospira, (now Pfizer) as a program manager responsible for international alliances. Before entering the pharmaceutical industry, she was the Chemical Technology Division Manager at Alion Science and Technology, a Department of Defense contractor. She earned her Ph.D in Analytical Chemistry from Purdue University and B.S. degree in Chemistry from Benedictine University. 

Tom has held various positions in clinical research in industry and academic settings. Prior joining Xentria, Tom served as a Senior Researcher at Olympus Corporation, focusing on interventional pulmonology solutions. His research career began at Northwestern University and Lurie Children’s Hospital of Chicago, primarily focused on asthma and cystic fibrosis therapeutics. Previous to this, Tom practiced as a Registered Respiratory Therapist in adult and pediatric critical care settings at various hospitals in Chicago and Indianapolis.

Tom holds a Bachelor of Science in Respiratory Care from Indiana University and a Master of Public Health, focused in Epidemiology and Healthcare Management, from Benedictine University. His research interests are centered in pulmonology, inflammatory disorders, critical care medicine, and rare diseases. His professional interests are centered in building and supporting efficient clinical development programs to fulfill unmet needs for suffering patients.

Noopur Singh is the Director of Medical Affairs overseeing Xentria’s advocacy efforts and fostering collaborative relationships with patient experts, key opinion leaders and clinical investigators. Motivated to eliminate challenges to drug access, Noopur is focused on strategic patient-centered drug development that bridges scientific gaps and cuts through the red tape across the drug supply chain.

Prior to Joining Xentria, Noopur was the Research Director at the Foundation for Sarcoidosis Research and played a key role in the development and execution of the organizations scientific research agenda. Before her time at FSR, Noopur was Clinical Site Manager Synexus Clinical Research in Chicago, responsible for the direction and execution of clinical trials. Prior to that, Noopur held various roles at Lurie Children’s Hospital of Chicago where she managed over 25 industry-sponsored trials and was an active participant in the Therapeutics Development Network with the Cystic Fibrosis Foundation. With over 10 years of both lab and clinical research experience in genetic and autoimmune-related rare diseases, her research interests focus on patient-centered outcomes and integrating the patient journey into drug development. Noopur earned a B.S. in Kinesiology from the University of Michigan.

Dionne Howe is the Associate Director of Clinical Operations and provides clinical operations leadership and oversight for all study activities, and determines operational processes, systems, and standards to support effective clinical program management and compliance across trials and locations.

Dionne earned an M.B.A. from Foster School of Business at the University of Washington Seattle and a B.A. in Chemistry from the University of North Carolina at Wilmington. She started her career working for a CRO as a bench scientist, then transitioned to Quality Assurance, R&D and Clinical Operations. Since 2003 Dionne has held positions in clinical research as a Clinical Research Coordinator, Clinical Research Associate, Clinical Study/Trial Manager and Clinical Project Manager. Prior to joining the Xentria Team in April 2022, Dionne was a Senior Clinical Project Manager at ICON – Biotech/Oncology.

Archit has supported Xentria as an Alliance Manager leading the orphan drug biologics project since its inception. As Alliance Manager, Archie is responsible for managing the project timeline and budget and is the main point of contact tying the functional teams together across various partner companies. Archit facilitates alignment within the global supply chain, manufacturing, and R&D with Xentria’s clinical operations.

Prior 2020, Archit was a project manager at Kinbio located in Israel where he supported the R&D and manufacturing start-up efforts. Archit brings an intimate knowledge of the biologics and biosimilar manufacturing processes and project management skills to the lead biopharma projects from R&D through FDA approval. Archit holds a B.S. in Engineering from Southern Methodist University in Dallas, Texas.

Robert P. Baughman, MD serves as Xentria’s Lead Scientific Advisor, advising the company on strategy as well as research and development activities. Dr. Baughman received his MD from Case Western Reserve University School of Medicine and completed his fellowship at University of Cincinnati, University Hospital. He is board certified in Internal Medicine and Pulmonary Disease.

During his long and illustrious career as a practicing pulmonologist and Professor of Medicine at the University of Cincinnati, Dr. Baughman specialized in researching lung and respiratory diseases and undertook significant work on potential treatments for sarcoidosis. 

He is published widely, with over 300 original papers and more than 100 review articles and book chapters. In addition to his academic work, he sits on multiple medical journal editorial boards and has been actively involved in the Foundation for Sarcoidosis Research, dedicated to finding a cure for sarcoidosis and to improving care for sarcoidosis patients around the world.

Keith Robinson, MD, MS, FCCP serves as Xentria’s medical lead and key scientific advisor. Dr. Robinson is Senior Medical Director with the Medical & Scientific Management group of Syneos Health. He is a board certified Pulmonary Medicine and Critical Care Medicine physician with over 17 years of clinical experience.

Before Syneos, Keith worked as an Intensivist and Pulmonary Medicine Consultant with Pulmonary Physicians of South Florida, LLC, serving as Medical Director of Fusion Health Pulmonary Rehabilitation & Wellness for 7 years.

Dr. Robinson completed medical training at Indiana University School of Medicine and his residency in internal medicine at the University of Florida College of Medicine. He completed a fellowship in Pulmonary and Critical Care Medicine at the University of California, San Diego.

His professional activities include 10 years of clinical research as a principal investigator, focused in pneumonia, asthma, COPD, and pulmonary hypertension trials. In addition, Keith has spent 11 years as a consultant and advisor to Astra Zeneca, Mylan, Theravance, Sunovion, Actelion, CAIRE Industries, and AG Industries.

Over the last 14 years, she has worked in various operational positions within clinical research, focused primarily on oncology and respiratory therapeutic indications.  She began her career working for a central institutional review board (IRB), as a Study Manager, overseeing study submissions for several large pharmaceutical clients. 3 years following, Amanda moved into industry and has since then led pharmacovigilance and clinical operations as a project manager for various companies, including OncoGenex Pharmaceuticals, Chiltern Inc, and Olympus Corporation.  Amanda recently transitioned to consulting to focus her efforts on helping small biotech companies create compliant and meaningful clinical and pharmacovigilance processes.

Amanda earned her Bachelor of Arts degree from the University of Washington in Global Studies, Technology & Human Rights. Despite transitioning out of the IRB realm, research ethics and human subject safety are deeply engrained in her practice and her primary focus when it comes to trial conduct and process deployment.

Tom Hoggan is a UK based consultant who supports Xentria to identify and evaluate potential assets through our network of development partners. He leads the translation of concepts to comprehensive clinical development plans, including target product profiles, value proposition, regulatory strategy, and clinical study protocol development. He has worked in the research industry since 2006, supporting many biotech and large pharma companies to navigate the clinical development pathway to successful market approval or exit strategy.

Tom began his research career in early phase clinical development at ICON. In 2012, he began a two-year stint with the UK’s National Institute of Health Research, where he advised biotech and pharma companies on the successful development of clinical study protocols, and subsequent execution of those studies in the UK. In 2014, Tom joined Parexel where he held strategic positions of increasing responsibility and scope, eventually becoming global strategy lead in the Immunology & Inflammation therapeutic franchise.

Tom is passionate about developing creative and adaptive development pathways for new assets, with the ultimate goal of expediting the availability of new medicines to patients in need.